Introduction
In eutherian mammals, the placenta is responsible for directly mediating or modulating the maternal environment required for maintenance of normal fetal growth and development.
The placenta is the site of nutrient and waste transfer between the mother and fetus, serves as a barrier against pathogens and the maternal immune system, and functions as an active endocrine organ. Among the hormones synthesized and secreted by the placenta are members of the growth hormone (GH)/prolactin gene family, including the placental lactogens (PLs), prolactin-related proteins (PRPs) and placental growth hormone (GH-V; Roberts and Anthony, 1994) . Most species that have been examined secrete one or more of the placental members of this family; horses, pigs and rabbits are exceptions. Primates secrete both PL and GH-V, whereas non-primate species produce one or more PLs and, at least in rodents and ruminants, one or more PRPs.
Although ruminant PLs have been known to exist for approximately 20 years, and the PLs expressed by bovine and ovine placentae were amongst the earliest purified to homogeneity, we still cannot draw firm conclusions about their regulation, their exact mechanism of action nor their specific biological functions. Use of recombinant DNA methods led to the discovery of mRNA encoding PRPs within the bovine placenta (Schuler ef al., 1991) . However, their existence in other ruminant placentae has yet to be reported, and we know even less about the regulation and function of the ruminant PRPs than we do about the PLs. This review will focus on our current knowledge of structure, regulat on, mechanism of action and proposed functions of the ruminant PLs and PRPs.
Structure and Regulation of Ruminant Placental Lactogens and Prolactin-related Proteins

Primary structure
Placental lactogens have been purified from the placentae of cattle (Murthy et al., 1982) , goats (Currie et al., 1990) and sheep (Warren et al., 1990b) , and the primary structures of bovine PL (bPL: Schuler et al., 1988) and ovine PL (oPL: Warren et al., 1990b) have been determined by a combination of amino acid and cDNA sequencing. Both bPL and oPL ( Fig. 1) are structurally more similar to prolactin than they are to GH in both nucleotide and amino acid sequence. Although bPL and oPL are more similar to each other than they are to other members of this gene family, the interspecific divergence in the primary sequence of the ruminant PLs is greater than the interspecific divergence of either prolactin or GH. Analysis of ruminant PL sequence similarities (Wallis, 1993) indicated that the rate of nonsynonymous substitution was greater than the rate of synonymous substitution, leading to the suggestion that the more rapid rate of evolution between bPL and oPL resulted from adaptive rather than from neutral mutations.
Ovine PL is a nonglycosylated polypeptide with an apparent Mr of 22 000 (Warren et cll., I990a), which appears to undergo little post-translational processing other than removal of a 38 amino acid leader peptide (Warren et al., 1990b) . Caprine PL (Currie et al., 1990) (Byatt et al., 1990) , whereas removal of 0-linked oligosaccharides has no effect on receptor binding. None of the ruminant PLs has been crystallized, so it remains unclear whether the differences in their primary sequence and occurrence of glycosylation result in overall structural divergence sufficiently significant to alter function.
In cattle, the placenta can produce at least six prolactin-related proteins (Schuler et al., 1991) that are structurally distinct from PL (Fig. 1) . All bovine prolactin-related proteins (bPRPs) were identified by screening placental cDNA libraries, and are predicted to be glycoproteins containing Asn-linked oligosaccharide chains. The six bPRPs, as a group, are structurally more similar to each other than they are to PL, prolactin or GH, but there is considerable diversity among the bPRPs in their primary amino acid sequences (Fig. I) . Translation of bPRP-I has been demonstrated (Zieler et al., 1990) , and it exists as two Mr forms ( z.J,34 000 and 35 000) each containing Asn-linked oligosaccharide chains. Identification of prolactin-related proteins or their mRNA in other ruminant placentae has not been reported. However, we (E. P. Kayl and R. V. Anthony, unpublished) have preliminary evidence from reverse transcriptase-polymerase chain reaction of ovine placental mRNA that there are at least three analogous prolactin-related proteins in sheep.
Gene structure and expression
Structural genes encoding bPL, bPRP-1 and oPL have been isolated and characterized (Ebbitt et al., 1989; Kessler and Schuler, 1991; Liang and Anthony, 1993) . All three genes comprise five exons and four introns, and the exons of each gene span 10 -12 kilobases (kb) of DNA. At least in cattle, all placental members of this gene family are linked on chromosome 23 with the bovine PRL gene (Dietz et aL, 1992) . Consensus sequences for activator protein-1 and -2 response elements reside within the immediate 5' flanking regions of the bPL and oPL genes, which may be involved in basal promotor activity. As yet, neither these response elements nor other putative response elements identified by sequence analysis have been tested for functionality. The lack of ruminant-derived chorionic cell lines has hindered a thorough characterization of the transcriptional control of these genes. Gene copy number was not determined for the bPL or bPRP-I genes, but we have evidence that oPL is encoded by a single copy gene (R. Liang and R. V. Anthony, unpublished) . However, evidence for differential splicing of the bPL transcript and allelic variants of the bPL gene has been reported by Yamakawa et al. (1990) and Kessler and Schuler (1991) .
Bovine PL, bPRP-I and oPL are products of chorionic binucleate cells (Milosavljevic et al., 1989; Kappes et al., 1992; Fig. 2) , which deliver their products to the maternal circulation by migrating to and fusing with the feto-maternal syncytium (Wooding, 1992) . Expression of bPL and bPRP-I mRNA has been detected as early as day 17 of gestation (Kessler et al., 1991) , and their expression appears to increase at least until day 140 of gestation. Expression of oPL mRNA increases from day 60 to day 120 of gestation (Kappes et al., 1992 ) when it appears to reach a plateau (Fig. 3) . However, if the concentration of oPL mRNA is expressed on a per cell basis, expression does not change from day 60 to day 135 of gestation (Kappes et al., 1992) . The percentage of chorionic epithelial cells that are binucleate remains constant during this time (Wooding, 1982) , but as gestation progresses there is an increase in the total amount of chorionic epithelium within the placentome. Taken together, these results suggest that the increase with gestational age in concentrations of oPL mRNA was a result of increased total chorionic epithelial cells, including a proportional increase in total chorionic binucleate cells (Kappes et al., 1992) . This raises the question of whether or not the primary regulator of oPL gene transcription is the progression of differentiation of chorionic primary cells into binucleate cells (i.e. constitutive expression). Until a system is developed to examine binucleate cell differentiation, this hypothesis will be difficult to test thoroughly.
Secretion
The interspecific divergence of ruminant PLs is not only observed with their primary amino acid sequences, but is also apparent in the amount of PL that reaches the maternal circulation. Ovine PL hypoglycaemia in either the mother or fetus (Brinsmead et al., 1981) , which leaves the identity of the stimulus in question.
Mechanism of Action of Ruminant Placental Lactogens
Cattle
An issue that remains to be resolved is the mechanism of action by which ruminant PLs and PRPs exert their effects. More specifically, the question relates to whether there are unique PL or PRP receptors. Specific binding sites for bPL have been identified in endometrium (Kessler et al., 1991) (1992) demonstrated that bovine endometrium, corpus luteum and fetal liver all contain mRNA encoding the bGH receptor, and Lucy et al. (1993) provided evidence that the corpus luteum contains protein that is immunoreactive with antisera raised against the bGHBP. These data raise the possibility that bPL is acting through the bGH receptor by binding to a different site on the receptor. However, if this is true, the question must be raised as to why specific bGH binding cannot be demonstrated with endometrial or luteal microsomal membranes (Kessler et al., 1991; Lucy ef al., 1994) . Lucy et al. (1993) observed two types of bGH receptor mRNA (4.4 and 4.7 kb) from luteal tissue and a single type (4.4 kb) from liver. It is possible that the 4.7 kb transcript encodes a variant form of the bGH receptor that retains its binding affinity for bPL, but has significantly reduced affinity for bGH owing to conformational changes in the receptor.
Scott et al. (1992) reported that the bovine prolactin (bPRL) receptor is also expressed by the corpus luteum, endometrium and fetal liver. When the bPRL receptor was expressed in COS cells (Scott et al., 1992) , bPL and bPRL exhibited similar affinity for this receptor (0.20 versus 0.31 nmol l -`;respectively), raising the possibility that in some tissues, bPL may be exerting its action through the bPRL receptor.
Recent evidence from our laboratory (Anthony et al., 1994) demonstrates that there are two forms of ovine prolactin (oPRL) receptor mRNA in adult ovary and fetal liver. One oPRL receptor mRNA (oPRLR-I) is predicted to encode a receptor analogous to the reported bPRL receptor (Scott et al., 1992; Fig. 4) , and one encodes a truncated form of the oPRL receptor (0PRLR-2). Termination of translation of oPRLR-2 (Anthony et al., 1994) is predicted to occur between Homology box I and 2 (DaSilva et al., 1994) , at a site analogous to that of the short-form prolactin receptors expressed in mice (Davis and Linzer, 1989) and rats (Boutin ef al., 1988) . Truncation of the rat PRL receptor between Homology box I and 2 disrupts the phosphorylation of and the association between JAK2 tyrosine kinase and the receptor (DaSilva et al., 1994) , although the affinity of prolactin is equivalent to that exhibited by the full-length receptor. If an analogous 'short' prolactin receptor is expressed in ruminants, it may bind PL or bPRP, possibly acting through a signal transducer other than JAK2.
Sheep
Binding of oPL has been examined most extensively with maternal and fetal liver microsomes (Freemark et al., 1986; Freemark and Corner, 1989) . Ovine PL expresses specific high-affinity binding (Kd cz:0.12-0.5 nmol 1-1-; Freemark and Corner, 1989; Pratt et al., 1991) to fetal liver microsomes, whereas ovine GH (oGH) or oPRL exhibits little to no specific binding to these membranes (Freemark et al., 1986) . Saturation analyses of oPL binding sites in fetal liver (Pratt et al., 1991) indicate that the concentration of the binding site does not change with increasing gestational age ( oPL, but no specific binding of oGH or oPRL. Freemark and Corner (1989) reported the partial purification of the maternal and fetal liver oPL binding site. The apparent Mr of this receptor was 44 000, with a 30-50 times greater affinity for oPL than for oGH (Freemark and Corner, 1989) , but no amino acid sequence information was reported.
Recent results from cross-linking and immunoprecipitation studies (Breier et al., 1994b) , 1992) . If the common receptor for oGH and oPL present in fetal liver (Breier et al., 1994b) is the oGH receptor, why does oGH not bind with equal or greater affinity than oPL. Furthermore, the sequence of the oGH receptor mRNA present during mid-gestation (day 60 to day 120 of gestation) in fetal liver differs within the 5'-untranslated region from the oGH receptor mRNA present at 135 days of gestation and in adult liver (Pratt and Anthony, 1993) . The major oGH receptor mRNA transcript present during midgestation is about 300 base pairs larger than oGH receptor mRNA expressed in maternal liver (Pratt and From the data available, firm conclusions cannot be drawn about the structure of the receptor for ruminant PLs. However, there are several possibilities about the identity of the PL receptor (Fig. 5) . One possibility is that PL binds a single monomer of the GH receptor; another possibility is that it binds a single monomer of the GH receptor and a yet undescribed receptor monomer. It is possible that PL acts by binding a modified GH receptor, such as one that has an extended amino terminus, that through conformational changes loses its affinity for GH but retains its affinity for PL (Fig. 5) . Finally, there may be a structurally distinct receptor for ruminant PLs. The structural characterization of the PL receptor may finally be accomplished using expression-cloning methods.
Function of Ruminant Placental Lactogens
Although the existence of ruminant PLs has been known for some time, their specific biological function(s) is not known. This is due to two factors, the first and more important is that classical ablation-replacement experiments are not feasible with placental hormones. This situation may be rectified in the future if ruminant embryonic stem cell lines become available to allow gene ablation experiments to be conducted. The second factor is the lack of highly purified biologically active ruminant PLs for functional studies. However, recombinantly derived bPL and oPL are now being used to determine their biological functions. Consequently, a more thorough understanding of the biological functions of these placental hormones should be forthcoming.
Mammotrophic actions
As their name implies, ruminant PLs may act on the mammary gland. Induction of mammogenesis in nonpregnant ewes is inhibited if prolactin secretion is prevented by administration of bromocryptine (Schams et al., 1984) , but in pregnant sheep, mammary development occurs in the absence of prolactin secretion, suggesting the presence of a conceptus-derived mammotrophic agent (Schams et al., 1984) .
However, oPL is not as efficient as prolactin in stimulating 13-casein mRNA transcription in ewe mammary gland explants (Serverly ei al., 1983), and does not compete for prolactin binding sites in mammary tissue (Emane et al., 1986) . The latter data were interpreted to suggest that oPL does not play an important role in mammogenesis and lactation. It is possible that the conceptus-derived mammotrophic agent (Schams et al., 1984) is not PL but a prolactin-related protein, although there is no evidence to support this hypothesis.
In cattle, as in sheep, inhibition of prolactin secretion during pregnancy does not impede mammary development (Schams et al., 1984) . However, in contrast to sheep, bPL can bind the bPRL receptor with high affinity (Scott et al., 1992) . Furthermore, bPL stimulates DNA synthesis in bovine mammary gland explants maintained in athymic nude mice (Vega et al., 1989) . Recent evidence (Byatt et al., 1994) demonstrated the ability of bPLs to stimulate mammary growth and DNA synthesis. Bovine prolactin also stimulated mammary growth but did not significantly increase DNA synthesis. Both hormones induced milk synthesis, although prolactin was more potent than bPL, and bPL stimulated greater mammary secretion of the insulin-like growth factor binding proteins (IGFBP-2 and -3) than did prolactin (Byatt et al., 1994) . These data suggest that bPL may stimulate mammogenesis and lactat on.
Luteotrophic actions
Several lines of evidence support the hypothesis that rodent PLs or prolactin-related proteins play a luteotrophic role during pregnancy. However, evidence for a similar role for ruminant PLs is lacking. Ovarian infusion with oPL does not increase progesterone secretion (Schramm et al., 1984) and short-term immunoneutralization of oPL does not alter progesterone concentrations in pregnant ewes (Waters et al., 1985) . Furthermore, oPL does not appear capable of inhibiting the luteolytic actions of PGF,,, (Schramm et al., 1984) . These data shed doubt on any proposed action of oPL as a luteotrophin.
However, recent evidence in cattle (Lucy et al., 1994) indicates that bPL injections will increase luteal size and plasma concentrations of progesterone, and reduce the size of the largest follicle. Some, but not all, of these effects were obtained with bGH injections (Lucy et al., 1994) . It is not yet clear whether the bGH receptors present in bovine luteal tissue (Lucy et al., 1993) are functional receptors capable of mediating these actions, or whether the larger bGH receptor transcript is encoding a receptor responsible for these actions. Until more is known about the structure and function of bPL-binding sites in corpora lutea, firm conclusions cannot be drawn about the role of bPL as a luteotrophic hormone.
Maternalandfetal metabolism
Efforts to define the effects of PLs on maternal and fetal metabolism have focused primarily on the effects of human PL and oPL, but much of the available information was obtained using interspecific assays. Figure 6 shows the possible role of oPL in repartitioning maternal nutrients to the fetus and how oPL stimulates the fetus to use these substrates. However, as will be discussed, there is insufficient data to support or refute many of the hypotheses about the role of PL during pregnancy.
Infusion of partially purified oPL for 8 h to fasting pregnant and nonpregnant ewes decreased plasma concentrations of non-esterified fatty acids, glucose and amino nitrogen, but an increase in plasma insulin was observed (Handwerger et al., 1976) . In contrast, infusion of a placental extract, enriched for oPL, for 36 h into nonpregnant ewes resulted in increased plasma non-esterified fatty acids, glucose and urea nitrogen, with no effect on plasma insulin (Thordarson et al., 1987) . In addition, short-term (12 h) immunoneutralization of maternal oPL did not significantly affect whole body glucose metabolism, but there was a trend for lower plasma non-esterified fatty acids and a significant increase in plasma insulin (Waters et al., 1985) . It is difficult to reach any firm conclusions from the results of these three reports as the experimental approach differed, especially in regard to dose and purity of oPL, pregnancy status and gestational age. Further research is required to determine the effects of oPL on maternal metabolism. The nutritional status of the ewes must be normalized across experiments, as fasting will increase oPL concentrations in both maternal and fetal circulation (Brinsmead et al., 1981) , and reduce the concentration of oPL binding sites in maternal and fetal liver (Freemark et al., 1992) . The latter effect of fasting can be reversed by glucose infusion (Freemark et al., 1992) , suggesting not only nutritional regulation of oPL secretion but also of its function.
In cattle, administration of bPL to pregnant or nonpregnant, non-lactating cows did not increase concentrations of non-esterified fatty acids, glucose, tri-iodothyronine and insulin in plasma, whereas administration of bGH increased all of these parameters (Byatt et al., 1992) . However, bGH and bPL increased plasma concentrations of IGF-I and IGF-II, and decreased the concentrations of blood urea nitrogen and IGFBP-2. Lucy et al. (1994) also noted an increase in circulating IGF-I when nonpregnant heifers were injected with bPL. These data from cattle are in contrast to at least some of the data available for sheep (see above), and the reasons for these differences are not known.
However, Byatt et al. (1992) concluded that bPL was not necessarily acting as a GH agonist, but rather bPL elicited distinct effects on intermediary metabolism that may be mediated through another specific receptor.
If the role of PL is to repartition nutrients for fetal use (Fig. 6) interpretation of these results must be tempered by the realization that oPL is not acting through oPL-specific receptors in these tissues. At least one of these actions occurs in fetal sheep tissues. Treatment of ovine fetal hepatocytes with oPL stimulated dose-dependent increases of glucose incorporation into glycogen and total cellular glycogen content (Freemark and Handwerger, 1986) . Both oGH and oPRL stimulated glycogen synthesis by fetal hepatocytes, but their potencies were considerably less than that of oPL (12% and 4% of oPLs potency, respectively). In addition, infusion of oPL at a rate of 1.2 mg day for 14 days into fetal vasculature (days 122-135 of pregnancy) increased fetal serum IGF-I concentrations, but did not affect serum IGFBP-2 (Table 2 ; Schoknecht et al., 1992b) . Although these last results are not conclusive, they support the hypothesis that oPL may directly or indirectly stimulate IGF production by the fetus, thereby providing anabolic stimulation to the fetus.
The hypothesis shown in Fig. 6 is neither conclusively supported or refuted by the available data. It is clear that ruminant PLs can bind the GH receptor, and it is plausible that the role of PL in the maternal circulation is to augment or modulate the actions of GH within the mother. This may be accomplished by mediating its action through the GH receptor rather than by a structurally distinct receptor. However, some of the actions of GH (for example diabetogenic actions) may not be advantageous to the fetus, and actions of PL through a structurally distinct receptor may provide a more generalized anabolic fetal environment.
Future research on the biological function of ruminant PLs must take into account that during pregnancy there are two separate metabolic units (mother versus fetus).
Conclusions
Placental members of the GH/prolactin gene family are true placental hormones that are not synthesized or secreted by other endocrine glands. In ruminants, these include the PLs and prolactin-related proteins. Considerable progress has been made in defining the primary structure and gene organization of these placental hormones.
However, we do not know what specifically regulates production of these hormones, their mechanism of action or their specific biological functions. This is particularly true for the family of ruminant prolactin-related proteins. Ruminant PLs may act through receptors other than GH or prolactin receptors, but this remains controversial and will be resolved only when specific PL binding sites are structurally characterized. Methods are now available to incorporate a functional binding assay into the search for PL receptors, and these methods should be used for both maternal and fetal tissues. Finally, there is a need to define the function(s) of this placental gene family. These research efforts must take into consideration the pregnancy status, gestational age and nutritional status of the experimental animals. With the availability of recombinantly derived hormones, and availability of gene ablation on the horizon, the function of this placental gene family may finally be resolved.
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